Literature DB >> 14586890

Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation.

Mitchell L Shiffman1.   

Abstract

1. Chronic infection with hepatitis C virus (HCV) is the leading cause of cirrhosis and the most common indication for liver transplantation in many countries throughout the world. 2. The most significant factors leading to fibrosis progression in patients with chronic HCV infection include the degree of inflammation present on liver biopsy and ongoing alcohol use. 3. Patients with cirrhosis secondary to chronic HCV infection are at increased risk for developing hepatocellular carcinoma (HCC). 4. Achieving a sustained virological response after treatment with interferon, with or without ribavirin, is associated with a reduced risk for the development of cirrhosis and HCC and prolonged survival.

Entities:  

Mesh:

Year:  2003        PMID: 14586890     DOI: 10.1053/jlts.2003.50254

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  4 in total

1.  A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.

Authors:  David B Olsen; Anne B Eldrup; Linda Bartholomew; Balkrishen Bhat; Michele R Bosserman; Alessandra Ceccacci; Lawrence F Colwell; John F Fay; Osvaldo A Flores; Krista L Getty; Jay A Grobler; Robert L LaFemina; Eric J Markel; Giovanni Migliaccio; Marija Prhavc; Mark W Stahlhut; Joanne E Tomassini; Malcolm MacCoss; Daria J Hazuda; Steven S Carroll
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial.

Authors:  Piyawat Komolmit; Kriangsak Charoensuk; Kessarin Thanapirom; Sirinporn Suksawatamnuay; Panarat Thaimai; Chintana Chirathaworn; Yong Poovorawan
Journal:  PLoS One       Date:  2017-04-04       Impact factor: 3.240

3.  This is hepatitis--it is closer than you think.

Authors:  James Fung; Man-Fung Yuen
Journal:  Indian J Med Res       Date:  2012-07       Impact factor: 2.375

4.  Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus.

Authors:  Masayoshi Yada; Masayuki Miyazaki; Kosuke Tanaka; Akihide Masumoto; Kenta Motomura
Journal:  World J Gastroenterol       Date:  2018-04-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.